Simvastatin Inhibits Endometrial Cancer Malignant Behaviors by Suppressing RAS/Mitogen-Activated Protein Kinase (MAPK) Pathway-Mediated Reactive Oxygen Species (ROS) and Ferroptosis

Figure 6

RAS agonist reverses the promoting effects of simvastatin on ROS level and ferroptosis in Ishikawa cells. (a–b): flow cytometry detected the effects of simultaneous treatment of ML-098 and simvastatin on DCFH-DA-labeled ROS level in Ishikawa cells; (c–d): ELISA detected the effects of simultaneous treatment of ML-098 and simvastatin on the level of MDA (c) and GSH (d) in Ishikawa cells; (e): ELISA to detect the effect of simultaneous treatment of ML-098 and simvastatin on the Fe²⁺ level in Ishikawa cells; (f-g): Western blot to determine the effect of simultaneous treatment of ML-098 and simvastatin on the expression of ferroptosis-related proteins (SLC7A11, TRF1, and FPN) in Ishikawa cells, vs. control group; ^## vs. simvastatin group. ROS, reactive oxygen species; MDA, malondialdehyde; GSH, glutathione; solute carrier family 7 member 11; TRF1, transferrin receptor 1; FPN, ferroportin.

(a)

(b)

(c)

(d)

(e)

(f)

(g)